# Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM

> **NCT02981069** · PHASE4 · COMPLETED · sponsor: **The University of Texas Health Science Center at San Antonio** · enrollment: 90 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Exenatide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02981069
- **Lead sponsor:** The University of Texas Health Science Center at San Antonio
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-15
- **Primary completion:** 2022-07-14
- **Final completion:** 2023-03-19
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2023-07-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02981069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02981069, "Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02981069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*